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HIGHLIGHTS 
 Definition and mechanisms of protein transduction delivery system based on HIV-TAT 
domain/peptide. 
 Introduction of a novel TATκ (TATkappa), synthetic TAT peptides which was established by 
Professor Farzin Farzaneh from King’s College London, UK. 
 Discussion and comparison of the pioneer work using this novel TATκ by our group with most 
efficient used TAT33 peptide. 
 The potential of using TAT domain as a tool delivery of transcription factors as an alternative for 
generating induced pluripotent stem cell (iPSC) for safer clinical applications.  
 Modifications, evolution and future directions of using TAT peptide for efficient delivery of 
proteins/factors are also discussed. 
Abstract 
Induced pluripotent stem cells (iPSC) are somatic cells reprogrammed to pluripotency by 
forced expression of pluripotency factors. These cells are shown to have the same pluripotent 
potential as embryonic stem cells (ESC) and considered as an alternative to the much 
controversial usage of ESC which involved human embryos. However, the traditional method 
in reprogramming cells into iPSC using genome-integrating retro- or lenti- viruses remains an 
obstacle for its application in clinical setting. Although numerous studies have been conducted 
for a safer DNA-based reprogramming, reprogramming of iPSC by genetic modifications may 
raise the possibility of malignant transformation and has been a major limitation for its usage 
in clinical applications. Therefore, there is a need for an alternative method to reprogram the 
cells without the use of gene editing and a much safer way to deliver transcription factors to 
induce pluripotency on target cells. Using protein transduction approach, a number of studies 
have demonstrated the generation of human iPSCs from human fibroblasts and mouse 
embryonic fibroblasts by direct delivery of reprogramming proteins. In this review, the definition 
and mechanism of HIV-TAT protein (a type of protein transduction domain) in delivering 
recombinant proteins, including the potential of protein-based delivery to induce iPSC were 
further discussed. 
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Introduction 
Since the revolutionary method of reprogramming somatic cells by retroviral vectors in 2006, 
(Takahashi and Yamanaka, 2006) subsequent studies later confirmed the generation of 
induced pluripotent stem cells (iPSCs) from human by forced expression using a panel of 
pluripotency factors (KLF4, Oct-3/4, Sox2 and c-Myc) (Wernig et al., 2007; Takahashi et al., 
2007; Park et al., 2008). These iPSCs were indistinguishable from embryonic stem cells, with 
the ability to differentiate into various cell types. However, the use of genome-integrating 
retroviruses in these reprogramming methods, remain an obstacle for iPSC application in a 
clinical setting as it may cause unpredictable genetic dysfunction (Yamanaka 2007; Okita et 
al., 2007). Furthermore, a case of insertional mutagenesis in patient treated with retroviral 
mediated gene therapy limits the potential of iPSC generated from retrovirus delivery to be 
used in clinical settings (Hacein-Bey-Abina et al., 2003). To address these limitations, few 
strategies in silencing the transgenes in lentivirus delivery such as using inducible expression 
system (Brambrink et al., 2008; Soldner et al., 2009), has been reported. Other than viral 
delivery, transient transfection of piggyBac transposon with Cre-mediated excisable system 
has also been developed albeit with lower transfection efficiency (Kaji et al., 2009; Woltjen et 
al., 2009). Although all of these methods may provide a safer DNA-based reprogramming, 
integrative reprogramming could still induce genetic and epigenetic modification which resulted 
in somatic coding mutations (Gore et al., 2011). 
Since then, many strategies to avoid random integration in reprogrammed cells has 
been explored through non-genetic manipulation techniques using Sendai virus (SeV) (Fusaki 
et al., 2009), synthetic mRNA (Warren et al., 2010), mirRNA (Miyoshi et al., 2011) and 
episomal plasmid (Yu et al., 2009). In terms of reprogramming efficiencies, mRNA is reported 
to be higher than episomal and SeV but a survey throughout the reprogramming laboratory 
community around the world reveals 41% of the respondents could not achieved successful 
reprogramming by RNA method (Schlaeger et al., 2015). Thus, while highly efficient, RNA 
reprogramming proved to be challenging even in experienced laboratories. In terms of potential 
usage in clinical setting, episomal reprogramming method has been reported to be robust with 
higher reprogramming efficiencies than mRNA method in patient derived primary cell lines 
even under feeder free settings (Goh et al., 2013). However, among the limitations of episomal 
reprogramming are its low efficiency and elaborate combination of reprogramming factors 
other than the established four (Yu et al., 2009). Recent study also reported that further 
optimisation of culture condition is needed to achieve a complete transgene free 
reprogramming using episomal plasmids (Li et al., 2016). 
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Another completely different approach towards transgene free cell reprogramming is 
through the usage of small molecules and chemicals. In 2008 paper, Huangfu et al., has 
reported the use of histone deacetylase (HDAC) inhibitor, Valproic Acid (VPA) to improve 
reprogramming efficiencies (Huangfu et al., 2008). Since then, the usage of small molecules 
and chemicals to facilitate reprogramming through induction or by replacing one or two 
reprogramming factors have been widely explored (Lyssiotis et al., 2009; Li et al,. 2009; Shi et 
al., 2008). Small molecules and chemicals could modulate epigenetic mechanism and activate 
endogenous gene expressions through various signaling pathways in rapid, reversible and 
dose dependent manner (Huangfu et al., 2008; Mikkelsen et al., 2008). Although the usage of 
chemicals allows the ease of handling and administration, a comprehensive downstream 
screening is needed should it be used in clinical settings.  
Protein-based delivery gained attention with the discovery that treatment of somatic 
cells with embryonic carcinoma (EC) and embryonic stem cell (ESC) cellular protein extracts 
could induced pluripotency and epigenetic reprogramming  (Taranger et al., 2005); Freberg et 
al., 2007). Both studies relied on the permeabilization of cell membranes to facilitate delivery 
of cell extracts into cells. Permeabilization of cell membrane is crucial as the absence of 
streptolysin-O (SLO) treatment hindered the up-regulation of pluripotency genes (Bru et al., 
2008). In 2010 paper, Cho et al., thoroughly explored the potential of protein-based 
reprogramming and reported a successful generation of human iPSC using only a single 
transfer of ESC-derived protein extracts (Cho et al., 2010). Hence, protein-based delivery is 
thought to be a potential alternative in reprogramming cells.  
By using cell permeable protein transduction approach, protein could be delivered 
easily into cells without the use of permeabilization agent such as SLO (Ford et al., 2001). 
Protein transduction method was also shown to be having higher advantage than viral 
transgene delivery in vivo (Barka and Van der Noen, 1996; Barka et al., 2000). This delivery 
method ensures no genomic integration and is a practical reprogramming alternative in clinical 
settings. The protocol using recombinant proteins is straightforward, and there is certainly no 
need for integration-free colonies selection. Furthermore, protein reprogramming allows better 
timing and control of reprogramming factors delivery in a concentration-dependent manner. 
One concern that should be addressed is the relatively low efficiency of these protein-based 
reprogramming. However, with recent progress in this field, a complete exogene-free iPSC cell 
line could possibly be generated using a highly efficient protein-based reprogramming. In this 
review, we discuss the various types of protein transduction system, their mechanism, and 
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introduction to HIV-TAT derived transduction systems and its variations. In addition, the recent 
progress in protein-based delivery application in iPSC cell reprogramming is also reviewed. 
Protein Transduction Technology 
Protein transduction can be best described as the introduction of proteins into target cells from 
the external environment. Some proteins and peptides are capable of being taken up by cells 
or can penetrate the cell membrane, when introduced exogenously (Ford et al., 2001). These 
proteins and peptides, usually either cytokines, homeoproteins or transcription factors, exhibit 
the unique properties of efficient translocation across cell membrane. This unique translocation 
is due to the presence of short amino acid sequences within the proteins, mediating cellular 
entry; which were identified as protein transduction domains (PTDs). PTDs are sometimes 
termed ‘cell permeable proteins’ (CPP) or ‘membrane translocating sequences’ (MTS) 
(Beerens et al., 2003). This technology has opened new avenues to transfer proteins and other 
molecules into target cells for therapeutic purposes.  
 PTDs that chemically fuse to other proteins confer the ability to similarly penetrate the 
cell membrane and even the nucleus. The three most widely studied PTDs are the Drosophila 
antennapeptide (Antp), the herpes simplex virus VP22 protein, and the HIV TAT protein 
transduction motif (Ford et al., 2001; Beerens et al., 2003; Noguchi and Matsumoto, 2006b). 
These PTDs are different in terms of their amino acid sequence and length (Table 1) 
(Schwarze et al., 2000). It has also been suggested that other proteins may have similar 
properties. These include fibroblast growth factor 1 and 2, and homeodomain (HD) containing 
proteins such as Hoxa-5, Hoxb-4, and Hoxc-8 (Prochiantz, 2000).  
The reason why PTDs are widely used are: (i) they confer the ability to deliver 
macromolecules into target cells, (ii) they are mainly independent of cell types, (iii) they are 
often very efficient, (iv) they are mostly stable, (v) they have very low or no cytotoxicity, (vi) 
they allow precise time and dose management and (vii) they usually cause no genetic 
modification of target cells. These features have made PTDs a promising alternative to deliver 
therapeutic proteins in a safe manner. 
The potential of TAT PTD to deliver therapeutic proteins for treatment of cancer has 
been widely studied. Although many studies have proven the uptake of TAT PTD fusion 
proteins by target cells, the trans-activation potential of endogenous cellular genes by the 11 
amino acids remains unclear. In addition, the full-length expression of TAT protein stimulates 
the growth of Kaposi’s sarcoma-derived cells (Ensoli et al., 1990) and TAT transgenic mice 
develop Kaposi’s sarcoma (Prakash et al., 2000). However, the use of the 11 amino acids of 
TAT PTD is shown to be non-toxic in vivo experiments as this small PTD sequence is 
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responsible for protein translocation only (Beerens et al., 2003). To date, no toxic effects or 
tumour transformed cells of abbreviated PTDs have been reported elsewhere. 
Intracellular Delivery of PTD-Conjugated Macromolecules 
Most studies have shown the ability of PTD fusion proteins to deliver a cargo of biologically 
active proteins (Barka and Van der Noen, 1996; Ho et al., 2001; Noguchi et al., 2004). 
However, the ability of PTDs to deliver a cargo into cells is not limited only to proteins or 
peptides. Other macromolecules including non-organic molecules fused or linked to different 
PTDs have also been shown to transduce into target cells efficiently. These macromolecules 
are antisense, short-interfering ribonucleic acids (siRNA), peptide nucleic acids (PNA), iron 
nanoparticles, liposomes, and plasmids (Prochiantz, 2000; Vives, 2003; Wadia and Dowdy, 
2003; Noguchi and Matsumoto, 2006b) (Table 2). 
Possible Mechanisms of Protein Transduction 
The mechanism of the internalization of PTDs is poorly understood. A few studies have shown 
that the internalization of TAT peptide is energy-dependent, requiring a temperature above 4 
ºC and ATP (Brooks et al., 2005). Nevertheless, many studies have demonstrated that the 
internalization of TAT-PTD, Antennapedia (Antp)-PTD or poly-Arginine (polyR)-PTD is not 
significantly inhibited by incubation at 4ºC, by inhibitors of endocytosis or by depletion of 
cellular ATP (Futaki et al., 2001). Also demonstrated is that PTD internalization does not 
depend on a specific primary sequence; hence, it is receptor-independent (Vives et al., 1997). 
A few models have emerged to explain PTD uptake into target cells by the perpendicular 
insertion of amphipathic peptides, electrostatic interaction or endocytosis.  
The first model is the perpendicular insertion of amphiphatic peptides into the 
membrane (Noguchi and Matsumoto, 2006b). This mechanism involves assembled 
hydrophilic-hydrophobic lipids forming a channel through oligomerization, allowing efficient 
passage of hydrophilic cargo. However, several peptides can form pores at the cell surface, 
thus would be a threat to cell survival by inducing apoptosis. Antp-PTD may be categorized in 
this model due to the presence of penetratin, which is derived from the third helix of the 
Antphomeodomain protein (position 43-58 amino acids) (Prochiantz, 2000). This peptide 
contains tryptophan (a hydrophobic amino acid) which is reported to be critical for the carrier 
ability in this model (Prochiantz, 2000).  
 A second model proposes electrostatic interaction between peptides binding to the 
polar heads of lipids in the membrane, resulting in the formation of inverted micelles that engulf 
the cargo. Interestingly, this process occurs even at 4ºC, thus confirming that the mechanism 
is temperature-independent. The micelle that was formed earlier will then re-open either in the 
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cytoplasm or nuclei of target cells. Some studies suggest that Antp-PTD might use this 
pathway (Berlose et al., 1996). It has also been suggested that HIV-TAT, which shares similar 
charge characteristics may also use this mechanism (Ford et al., 2001). However, a drawback 
of this model is that the inverted micelle formation would limit cargo size and it also requires 
the presence of hydrophobic amino acids, such features are absent in TAT PTD and poly-
arginine-PTDs.  
  
 A third model proposes cargo uptake by macropinocytosis, a type of endocytosis. It 
involves three phases which are: an electrostatic interaction with plasma membrane, 
macropinocytosis and retrograde transport (Figure 1). Most PTD-containing compounds are 
highly positively charged, while the plasma membrane is always negatively charged, thereby 
promoting PTD binding to plasma membrane due to electrostatic interaction. The initial step of 
transduction by PTDs occurs with electrostatic interaction with the plasma membrane, followed 
by the penetration into cells by macropinocytosis and release of the protein into cytoplasm and 
nuclei by retrograde transport to the Golgi apparatus and endoplasmic reticulum (Lord and 
Roberts, 1998; Noguchi and Matsumoto, 2006a). Macropinocytosis is the invagination of the 
membrane forming a pocket which then forms a vesicle filled with extracellular matrix (including 
molecules within it). The endocytosis pathway appears to be critically important for the 
internalization of PTD-containing compounds. 
HIV TAT Protein Transduction Domain  
The HIV-1 trans-activator gene product, TAT, has been shown to be a regulator of transcription 
in latent HIV and essential for HIV replication (Karn, 2011). It is an 86 amino acid protein 
consisting of two exons of 72 and 14 amino acids respectively. It has been reported that HIV-
TAT added exogenously in culture media was taken up efficiently by target cells (Green and 
Loewenstein, 1988). TAT amino acids 38-58 (the basic region of TAT) retain the transducing 
ability of HIV-TAT, which enables both nuclear and cytoplasmic uptake of the proteins (Mann 
and Frankel, 1991). This study also showed that the uptake was not inhibited by trypsinazation, 
heparinazation and neuramidazation of the cells. Furthermore, they speculated that TAT 
binding to the cellular membrane was mediated through charge-interaction between the basic 
region of TAT and charged polysaccharides on the cellular membrane of the target cells (Mann 
and Frankel, 1991).  
In subsequent studies, Green and Loewenstein (1998) have shown that the improved 
TAT (YGRKKRRQRRR) fusion proteins transduced better into target cells. This improved 
synthetic TAT domain corresponds to a short 11 amino acid region which is highly positively 
charged at physiological pH with nine out of 11 of its amino acids being either Arginine or 
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lysine. Since then, a series of synthetic TAT PTDs have been produced by optimising the 
deletion, addition and replacement of Arginine residues of primary TAT sequences, in order to 
determine their structure, activity relationship and the effect on internalization efficiency 
(Wender et al., 2000; Ho et al., 2001). 
 A few studies have demonstrated the ability of synthetic HIV-TAT to deliver several 
peptides and proteins into target cells. This includes poly-Arginine (polyR) and poly-lysine, 
which exhibit even greater delivery efficiency compared to the primary sequence of the original 
TAT (Futaki et al., 2001; Noguchi et al., 2004). Ho et al., (2001) reported the establishment of 
the improved synthetic TAT domains by α-helix modification of the original TAT structure 
(Figure 2) (Ho et al., 2001). These synthetic TAT domains were named as PTD-3, PTD-4, 
PTD-5, PTD-6, PTD-7 and PTD-8. The transduction efficiency was increased 5-fold in both 
PTD-3 and PTD-6, 8-fold in PTD-5 and 33-fold in PTD-4. However, the transduction efficiency 
of PTD-7 and PTD-8 peptides containing nine or seven Arginine residues was comparable with 
the original TAT peptide. In this review, the most studied peptide, PTD-4 will be further 
discussed together with the novel TATκ, established by Flinterman and colleagues in 2009 
(Flinterman et al., 2009). 
PTD-4 (also known as TAT33) 
PTD-4 was derived from the original TAT peptide by strengthening the putative α-helix with Ala 
(Alanine) residues (Ho et al., 2001). The Arg (Arginine) content of TAT33 was limited to three, 
which were closely aligned down the face of the α-helix structure (Figure 2C). This was done 
by synthesizing the original TAT peptide with an NH2-terminal FITC-Gly (Glycine) residue 
followed by a Gly-Gly-Gly motif (Glycine). The Ala residues were then placed accordingly at 
the appointed positions (2, 4, 5, 6, 9 and 11). This synthetic TAT33 showed dramatically 
increased transduction efficiency (up to 33-fold) as compared to the original TAT peptide. The 
differences in the amino acid sequence between TAT-33 and TAT are shown in Figure 3.  
 A study by Mi et al., (2000) demonstrated that the biotinlyted TAT33 and TAT peptides 
fused to avidin-beta-galactosidase were efficiently transduced in a variety of cell lines and 
primary cells (Mi et al., 2000). However, the transduction efficiency of TAT33 was comparable 
with TAT peptides. Another study also demonstrated that mice injected with either TAT33 or 
TAT peptides had about ~100% of their blood cells transduced 30 minutes post-intravenous 
injection. Additionally, FACS analysis showed 5-fold intracellular PTD-4-FITC accumulation 
compared to TAT peptide (Ho et al., 2001).    
TATkappa (TATκ) 
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TATκ was generated by introducing mutations to destroy the two furin cleavage sites that were 
present within the original TAT peptide (Figure 3). Furin is a human gene also known as PACE 
(Paired basic Amino acid Cleaving Enzyme) which belongs to the subtilisin-like 
proproteinconvertase family. Furin is enriched in the Golgi apparatus but can translocate 
between the trans-Golgi network and the cell surface (Denault and Leduc, 1996). The presence 
of these Furin sites in the TAT peptide results in the TAT peptide being cleaved from fusion 
proteins that are secreted via the constitutive pathway (Flinterman et al., 2009). Thus, the 
secreted protein will not be able to enter target cells and is trapped in the culture supernatant. 
Therefore, amino acid sequences RQRR and RKKR of TAT were modified by replacing five 
Ala residues within the peptide.  
 Flinterman et al., (2009) have established a novel system for the secretion of TAT 
fusion proteins using a mammalian expression system. Moreover, the ability of the secreted 
TATκ-GFP to efficiently transduce target cells was far greater than could be achieved with 
TAT-GFP or GFP alone. They also showed that the improved TATκ-GFP was efficiently 
secreted in culture supernatant compared to TAT-GFP confirming the presence of furin sites 
within the original TAT PTD. The secreted TATκ-GFP fused to Apoptin was also able to 
transduce into human osteosarcoma cell line (Saos-2) and induce apoptosis (Flinterman et al., 
2009).  
PTD usage in directing iPSC reprogramming 
Using protein transduction approach, Zhou et al., (2009) first showed generation of mouse iPS 
cells by transduction of purified 11 Arginine (11R)-tagged recombinant protein combined with 
chemical molecules such as valproic acid (VPA) (Zhou et al., 2009). The mouse iPS cells were 
able to be expanded more than 30 passages, generate three primary germ layers and give 
rise to chimeric mice. Subsequently, Kim et al., (2009) reported successful iPSC generation in 
human newborn fibroblast (HNF) cells using multiple treatments of cell extracts from stable 
HEK293 cell lines expressing four reprogramming factors Oct-4, Klf4, Sox2, c-Myc (OKSM) 
fused to 9 Arginine (9R). Encouragingly, these human iPSC were also able to differentiate into 
functional dopamine (DA) neurons and could significantly rescue motor deficits in Parkinson 
Disease (PD) rat model (Rhee et al., 2011).  In a 2012 paper, Zhang et al., (2012) described 
the comparison between the usage of 11R and TAT as protein transduction method in 
generating iPSC. It was found that recombinant proteins fused with TAT (TAT-RF) has a higher 
transcriptional activity compared to 11R-recombinant protein (11R-RF) suggesting TAT as the 
better choice as PTD for protein-based delivery (Zhang et al., 2012). The authors also reported 
higher efficiencies (0.012%) of iPSC reprogramming using five factors TAT-RF (with the 
addition of Nanog) combined with VPA treatment as compared to the previous studies (Zhou 
et al., 2009; Kim et al., 2009). In a later study, Nemes et al., (2014) employed a strategy using 
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transduction of GST-tagged TAT recombinant protein with a nuclear localization signal 
polypeptide (NLS) to further facilitate nuclear localization and successfully produced iPS cell 
lines which were able to incorporate into the blastocyst and generate chimeric offspring in mice 
(Nemes et al., 2014). In terms of functionality of the recombinant reprogramming proteins, 
Thier et al., has established a lipid-rich albumin supplement in a low serum culture conditions 
for protein delivery of TAT-Oct-4, and TAT-Sox2. Both recombinant proteins are biologically 
active and able to be a substitute for their viral counterpart and in inducing iPSC 
reprogramming (Thier et al., 2010; Thier et al., 2012). 
Limitations and possible ways to overcome 
Although several studies have reported successful generation of iPSC (Zhou et al., 2009; Kim 
et al., 2009; Zhang et al., 2012; Nemes et al., 2014) the efficiency of iPSC generation, using 
protein transduction approach is significantly lower (about 0.001% of input cells) compared to 
viral transduction approach (about 0.01% of input cells) (Takahashi et al., 2007; Park et al., 
2008; Kim et al., 2009). In an effort to improvised reprogramming protocols using PTD, Lee et 
al., 2012 observed significant differences in the genes expression profiles of cell 
reprogrammed with retrovirus and protein transduction method. It was reported that a toll-like 
receptor 3 (TLR3) pathway which enables efficient pluripotency reprogramming was activated 
only in retroviral induced cells as opposed to protein-based delivery (Lee et al., 2012). The 
study concluded that innate immunogenicity induced by viral particles could activate the 
expression of inflammatory genes and enhance epigenetics regulation in favor of 
reprogramming. However, application of TLR agonists called polyinosinic-polycytidylic acid 
(Poly I: C) together with recombinant proteins delivery could induce reprogramming efficiency 
in a shorter time (Lee et al., 2012). This strategy of using identified small molecules in 
enhancing the reprogramming efficiencies by recombinant proteins delivery method have also 
been employed in other studies with encouraging results (Zhou et al., 2009; Zhang et al., 
2012).  Furthermore, the use of other small molecules such as butyrate, 8-bromoadenosine 
and thiazovivin in enhancing reprogramming efficiencies in other integrative and non-
integrative protocols have also been extensively reported (Mali et al., 2010; Lin et al., 2009; 
Wang and Adjaye, 2011). Thus, further study is needed to explore the potentials of other small 
chemicals in supporting protein-based reprogramming as a way to overcome its limited 
reprogramming capabilities.  
Another concern in direct delivery of recombinant factors into cells is the production 
and quality of recombinant proteins. TAT recombinant proteins could be produced using 
bacterial expression vectors in a highly efficient manner (Nagahara et al., 1998) however 
subsequent purification steps may caused recombinant proteins to be insoluble, denatured 
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and could affect its biological activity (Singh et al., 2015). Although numerous studies have 
shown that TAT and 9R denatured proteins could be refolded and regained its biological 
activity inside the mammalian cells (Kwon et al., 2000; Jin et al, 2001), denatured proteins 
were also thought to be one of the main cause of unsuccessful reprogramming in human 
somatic cells (Pan et al., 2010). As the quality of recombinant protein produced in mammalian 
cells is superior than the one produced in bacteria or yeast and largely employed in most 
pharmaceutical proteins (Wurm et al., 2004), mammalian cells expression system could be a 
potential alternative in the production of correctly folded protein with a functional post 
translational modification in reprogramming applications (Hartley,  2012)  . 
To date there has been only one study employing mammalian cells HEK293 for 
expressing the OSKM 9R-recombinant proteins and its subsequent direct application of cells 
extract to target cells (Kim et al., 2009). The authors observed that a single 16 hour exposure 
of protein treatment were not sufficient and concluded that continuous exposure to 
reprogramming factors is needed. They were only able to induce reprogramming in HNF 
through a multiple round of 16 hour protein treatments followed by 6 days incubation in hESC 
culture medium (Kim et al., 2009). This method while feasible could be laborious as multiple 
rounds of transduction is needed in a span of 8 weeks. As an alternative, we recently described 
a strategy to develop producer cell lines that could continuously express reprogramming 
factors for applications in the targeted cell lines through direct or indirect co-culture. Using a 
modified TAT protein TATκ, we have shown in our recent study a strategy in generating 293T 
cells secreting the pluripotent factors Oct-3/4 (Nordin et al., 2014). The luciferase assay 
analysis showed a weak biological activity of Oct-3/4 protein, which confirmed that these 
producer cells secreted TATκ fused to Oct-3/4 protein in culture medium and could be uptake 
by haematopoietic cell lines, Jurkat and FDCP-1 cells. Although there are limitations that 
needed to be addressed, this strategy using cell lines in expressing recombinant proteins could 
be potentially applied in the future for the generation of iPS cells by protein transduction. 
As an alternative to the perceived cumbersome approach in reprogramming using 
recombinant proteins, few studies have identified the feasibility of using self-penetrating 
proteins as an alternative approach. Native reprogramming Oct-4 protein were reported to be 
having self-penetrating capability and are able to be uptake into living cells as well as 
translocated to the nucleus (Harretheir et al., 2014). Other studies also reported the ability of 
various versions of Nanog and Sox2 proteins in retaining and promoting their reprogramming 
capabilities (Theunissen et al., 2011; Aksoy et al., 2013). Thus, with the use of reprogramming 
factor proteins either truncated or enhanced with transactivator domains, protein-based 
delivery method is still in the running towards the race in generating clinically safer iPSC. 
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Future directions 
When taken together with previous reports, protein transduction method is a feasible 
alternative in replacing integration-based reprogramming methods. However, more basic 
questions such as immunogenicity, protein half-life, protein concentration, and modes of 
delivery are important questions that need to be answered before this type of therapy can be 
considered for long-term and effective human applications. At the molecular level, it is unclear 
how proteins behave when interacting with the cell membrane to mediate entry.  It is thought 
that protein transduction across the cellular membrane resulted in partial or complete unfolding 
of the protein which may differ from one protein to another (Schwarze et al., 2000). In order to 
obtain biologically functional protein, the transduced protein requires refolding once inside the 
target cells (Bonifaci et al., 1995). Another consideration is to investigate phenotypic changes 
to determine how promising in vivo protein transduction really is by conducting animal studies.  
Recently, a growing number of studies have shown the feasibility of protein 
transduction method in replacing viral delivery methods for directing specific lineage 
differentiation. Direct lineage reprogramming gained much attention recently as a more 
feasible way to produce specific functional cell lines for usage in regenerative medicine (Xu et 
al., 2015). Specific lineage differentiation is mainly achieved through forced expression of 
known combinations of transcription factors specific to the cells such as cardiomyocyte (Ieda 
et al., 2010), neural stem cells (Han et al., 2012) and insulin-producing cells (Xu et al., 2013). 
Islas et al., (2012) first attempted to reprogram human dermal fibroblast into cardiac progenitor 
using recombinant TAT fused with MESP1 and ETS2 and obtained cardiac progenitor cells 
(Islas et al., 2012).). Dai et al., (2014) used recombinant TAT proteins fused to OSK factors 
(Oct-4, Sox2, Klf4) combined with small molecules to reprogrammed adipose derived stem 
cells into  corneal-endothelial (CE) like cells (Dai et al., 2014). In a comparison study, myogenic 
transcription factors, MyoD tagged with TAT protein (TAT-MyoD) were shown to have higher 
reprogramming efficiency than its wild type MyoD protein which is also capable to facilitate 
transduction in mouse primary cells (Hidema et al., 2011). 
Aside from HIV-TAT usage in protein transduction, several other studies reported the 
use of other protein-based delivery in directing differentiation. Transduction of Pdx1 and 
NeuroD protein which have intrinsic PTD sequences with the combination of MafA fused with 
11R were reported to induce differentiation of insulin-producing cells in mouse ES cells and 
mouse iPS cells (Kaitsuka et al., 2014). Hu et al., (2014) reported the application of C-end Rule 
(CendR) peptide to deliver transcription factor Sox2 to retinal pigmented epithelial cell (RPE) 
for reprogramming of functional neurons (Hu et al., 2014). Recently, one study applied QQ 
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reagent which allowed efficient protein transduction (Li et al., 2008) modified with Gata4, 
Hand2, Mef2c and Tbx5 with the combination of growth factors could induce 80% of HDF into 
cardiac progenitor cells and improved cardiac function after myocardial infarction in rat model 
(Li et al., 2015). Given these recent developments, protein transduction method has a great 
potential and future in directing lineage specific differentiation in vitro and in vivo, and 
subsequently could potentially be used in therapeutic application. 
In general, a few improvements could be explored in the near future; (i) identifying new 
potential protein transduction domains (PTDs) and improving the potential of existing PTDs to 
increase transduction into target cells, (ii) identifying potential chemical molecules that are non-
toxic to enhance transduction into target cells, (iii) to increase the refolding rates of transduced 
full-length proteins and domains, and (iv) to produce sufficient physiological levels of secreted 
proteins for large scale studies. As regards to the usage of HIV-TAT as PTD, more optimization 
needs to be performed in order to improve the protein transduction of pluripotency factors fused 
to TAT domain. As reported in our study, TATκ fusion with pluripotent factors could be potential 
method for directing reprogramming of cells (Nordin et al., 2014). However there is a need to 
identify the problems related to secretion of TATκ fusion proteins, to study the biological 
function of TATκ fusion proteins in target cells and, to establish in vitro functional assays for 
assessment of these fusion proteins. 
Therefore, understanding and improving the mechanisms involved in the direct delivery 
of PTD fusion proteins into target cells for iPS reprogramming could give the answer to these 
questions and allow an accurate assessment of the potential that this approach could offer for 
human therapeutic applications.  
In conclusion, the protein transduction system has several advantages over integrating 
vectors; (i) they effectively eliminate the potential risks associated with chromosomal 
integrations, and (ii) they are a simpler and faster approach without the need for sequential 
selection of integration-free transduced cells, and (iii) the continuous expression of 
pluripotency factors by producer cell line which can be withdrawn at any time point in culture 
as compared to permanent gene expression in integrating viral vector. In addition, the 
assumption that a protein transduction approach, as opposed to genetic modification avoids 
the risk of malignant transformation requires extensive investigation to be verified by both in 
vitro and in vivo studies. 
Conflict of interest: 
The authors declare no conflict of interest. 
References 
13 
 
Aksoy, I., Jauch, R., Eras, V.,Chng, W.B., Chen, J., Divakar, U., Ng, C.K, Kolatkar, P.R., and 
Stanton, L.W. (2013). Sox transcription factors require selective interactions with Oct4 and 
specific transactivation functions to mediate reprogramming. Stem Cells 31, 2632-46. 
Barka, T., and Van der Noen, H.M. (1996). Retrovirus-mediated gene transfer into salivary 
glands in vivo. Hum Gene Ther 7, 613-618. 
Barka, T., Gresik, E.W., and van Der Noen, H. (2000). Transduction of TAT-HA-beta-
galactosidase fusion protein into salivary gland-derived cells and organ cultures of the 
developing gland, and into rat submandibular gland in vivo. J Histochem Cytochem 48, 1453-
1460. 
Beerens, A.M., Al Hadithy, A.F., Rots, M.G., and Haisma, H.J. (2003). Protein transduction 
domains and their utility in gene therapy. Curr Gene Ther 3, 486-494. 
Berlose, J.P., Convert, O., Derossi, D., Brunissen, A., and Chassaing, G. (1996). 
Conformational and associative behaviours of the third helix of antennapedia homeodomain in 
membrane-mimetic environments. Eur J Biochem 242, 372-386. 
Bonifaci, N., Sitia, R., and Rubartelli, A. (1995). Nuclear translocation of an exogenous fusion 
protein containing HIV Tat requires unfolding. AIDS 9, 995-1000. 
Brambrink, T., Foreman, R., Welstead, G.G., Lengner, C.J., Wernig, M., Suh, H., and Jaenisch, 
R. (2008). Sequential expression of pluripotency markers during direct reprogramming of 
mouse somatic cells. Cell Stem Cell 2, 151-159. 
Brooks, H., Lebleu, B., and Vives, E. (2005). Tat peptide-mediated cellular delivery: back to 
basics. Adv Drug Deliv Rev 57, 559-577. 
Bru, T., Clarke, C., McGrew, M.J., Sang, H.M., Wilmut, I., and Blow, J.J. (2008). Rapid 
induction of pluripotency genes after exposure of human somatic cells to mouse ES cell 
extracts. (2008). Exp. Cell. Res. 314, 2634-42. 
Cho, H.J., Lee, C.S., Kwon, Y.W., Paek, J.S., Lee, S.H., Hur, J., Lee, E.J., Roh, T.Y., Chu, 
I.S., Leem, S.H., Kim, Y., Kang, H.J., Park, Y.B., and Kim, H.S. (2010). Induction of pluripotent 
stem cells from adult somatic cells by protein-based reprogramming without genetic 
manipulation. Blood 116, 386-395. 
Dai, Y., Guo, Y., Wang, C., Liu, Q., Yang, Y., Li, S., Guo, X., Lian, R., Yu, R., Liu, H., and 
Chen, J. (2014). Non-genetic direct reprogramming and biomimetic platforms in a preliminary 
study for adipose-derived stem cells into corneal endothelia-like cells. PLoS One 9, e109856. 
14 
 
Denault, J.B., and Leduc, R. (1996). Furin/PACE/SPC1: a convertase involved in exocytic and 
endocytic processing of precursor proteins. FEBS Lett 379, 113-116. 
Ensoli, B., Barillari, G., Salahuddin, S.Z., Gallo, R.C., and Wong-Staal, F. (1990). Tat protein 
of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. 
Nature 345, 84-86. 
Flinterman, M., Farzaneh, F., Habib, N., Malik, F., Gaken, J., and Tavassoli, M. (2009). 
Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 17, 334-342. 
Ford, K.G., Souberbielle, B.E., Darling, D., and Farzaneh, F. (2001). Protein transduction: an 
alternative to genetic intervention? Gene Ther 8, 1-4. 
Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. (2007). Epigenetic reprogramming 
of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol. Biol. Cell. 
18, 1543-53. 
Fusaki, N., Ban, H., Nishiyama, A., Saeki, K. and Hasegawa, M. (2009). Efficient induction of 
transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA 
virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 85, 
348-362. 
Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., and Sugiura, Y. (2001). 
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential 
as carriers for intracellular protein delivery. J Biol Chem 276, 5836-5840. 
Goh, P.A., Caxaria, S., Casper, C., Rosales, C., Warner, T.T., Coffey, P.J., and Nathwani, A.C. 
(2013). A systematic evaluation of integration free reprogramming method for deriving clinically 
relevant patient specific induced pluripotent stem cells (iPS) cells. PLoS One 26, e81622. 
Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., 
Giorgetti, A., Israel, M.A., Kiskinis, E., Lee, J,H., Loh, Y.H., Manos, P.D., Montserrat, N., 
Panopoulos, A.D., Ruiz, S., Wilbert, M.L., Yu, J., Kirkness, E.F., Izpisua Belmonte, J.C., Rossi, 
D.J., Thomson, J.A., Eggan, K., Daley, G.Q., Goldstein, L.S., and Zhang, K. (2011). Somatic 
coding mutations in human induced pluripotent stem cells. Nature 471, 63-7. 
Green, M., and Loewenstein, P.M. (1988). Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179-1188. 
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., 
Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M., and Fischer, A. (2003). A serious 
adverse event after successful gene therapy for X-linked severe combined immunodeficiency.  
N Engl J Med 348, 255-6. 
15 
 
Han, D.W., Tapia, N., Hermann, A., Hemmer, K., Hoing, S., Arauzo-Bravo, M.J., Zaehres, H., 
Wu, G., Frank, S., Moritz, S., Greber, B., Yang, J.H., Lee, H.T., Schwamborn, J.C., Storch, A., 
and Scholer, H.R. (2012). Direct reprogramming of fibroblasts into neural stem cells by defined 
factors. Cell Stem Cell 10, 465-72. 
Harreither, E., Rydberg, H.A., Amand, H.L., Jadhav, V., Fliedl, L., Benda, C., Esteban, M.A., 
Pei, D., Borth, N., Grillari-Voglauer, R., Hommerding, O., Edenhofer, F., Norden, B., and 
Grillari, J. (2014). Characterization of a novel cell penetrating peptide derived from human 
Oct4. Cell Regen (Lond) 31, 2.  
Hartley, J.L. (2012). Why proteins in mammalian cells?. Methods Mol Biol 801, 1-12. 
Hidema, S., Tonomura, Y., Date, S., and Nishimori, K. (2011). Effects of protein transduction 
with intact myogenic transcription factors tagged with HIV-1 Tat-PTD (T-PTD) on myogenic 
differentiation of mouse primary cells. J Biosci Bioeng 113, 5-11. 
Ho, A., Schwarze, S.R., Mermelstein, S.J., Waksman, G., and Dowdy, S.F. (2001). Synthetic 
protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 
61, 474-477. 
Hu, Q., Chen, R., Teesalu, T., Ruoslahti, E., and Clegg, D.O. (2014). Reprogramming human 
retinal pigmented epithelial cells to neurons using recombinant proteins. Stem Cells Transl 
Med 3, 1526-34. 
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, D.A. 
(2008). Induction of pluripotent stem cells by defined factors is greatly improved by small-
molecule compounds. Nat Biotechnol 26, 795-797. 
Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B.G., and 
Srivasta, D. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by 
defined factors. Cell 142, 375-86. 
Islas, J.F., Liu, Y., Weng, K.C., Robertson, M.J., Zhang, S., Prejusa, A., Harger, J., 
Tikhomirova, D., Chopra, M., Iyer, D., Mercola, M., Oshima, R.G., Willerson, J.T., Potaman, 
V.N., and Schwartz, R.J. (2012). Transcription factors ETS2 and MESP1 transdifferentiate 
human dermal fibroblasts into cardiac progenitors. Proc Natl Acad Sci U.S.A 109, 13016-21. 
Jin, L.H., Bahn, J.H., Eum, W.S., Kwon, H.Y., Jang, S.H., Han, K.H., Kang, T.C., Won, M.H., 
Kang, J.H., Cho, S.W., Park, J., and Choi, S.Y. (2001). Transduction of human catalase 
mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian 
cells. Free Radic Biol Med 31, 1509-19. 
16 
 
Kaitsuka, T., Noguchi, H., Shiraki, N., Kubo, T., Wei, FY., Hakim, F., Kume, S., and Tomizawa, 
K. (2014). Generation of functional insulin-producing cells from mouse embryonic stem cells 
through 804G cell-derived extracelullar matrix and protein transduction of transcription factors. 
Stem Cells Transl Med 3, 114-27. 
Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K. (2009). Virus-free 
induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-
775. 
Karn, J. (2011). The molecular biology of HIV latency: breaking and restoring the Tat-
dependent transcriptional circuit. Curr Opin HIV AIDS 6 (1): 4-11. 
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., 
Cha, K.Y., Lanza, R., and Kim, K.-S. (2009). Generation of Human Induced Pluripotent Stem 
Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell 4, 472-476. 
Krosl, J., Austin, P., Beslu, N., Kroon, E., Humphries, R.K., and Sauvageau, G. (2003). In vitro 
expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat Med 9, 1428-
1432. 
Kwon, H.Y., Eum, W.S., Jang, H,W., Kang, J.H., Ryu, J., Ryong Lee, B., Jin, L.H., Park, J., 
and Choi, S.Y. (2000). Transduction of Cu, Zn-superoxide dismutase mediated by an HIV-Tat 
protein basic domain into mammalian cells. FEBS Lett 485, 163-7. 
Lee, J., Sayed, N., Hunter, A., Au, K.F., Wong, W.H., Mocarski, E.S., Pera, R.R., Yakubov, E., 
and Cooke, J.P. (2012). Activaion of innate immunity is required for efficient nuclear 
reprogramming. Cell 151, 547-558. 
Li, Q., Huang, Y., Xiao, N., Murray, V., Chen., J., and Wang, J. (2008). Real time investigation 
of protein folding, structure, and dynamics in living cells. Methods Cell Biol 90, 287-325. 
Li, S., Lan, H., Men, H., Wu, Y., Li, N., Capecchi, M.R., Bryda, E.C and Wu, S. (2016). 
Derivation of transgen-free rat induced pluripotent stem cells approximating the quality of 
embryonic stem cells. Stem Cells Transl Med 6 (2): 340-351. 
Li, W., and Ding, S. (2009). Small molecule that modulate embryonic stem cell fate and somatic 
cell reprogramming. Trends Pharmacol Sci 31, 36-45. 
Li, X.H., Li, Q., Jiang, L., Deng, C., Liu, Z., Fu, Y., Zhang, M., Tan, H., Feng, Y., Shan, Z., 
Wang, J., and Yu, X.Y. (2015). Generation of functional human cardiac progenitor cells by 
high-efficiency protein transduction. Stem Cells Transl Med 4, 1415-24. 
17 
 
Lim, J., Kim, J., Kang, J., and Jo, D (2014). Partial somatic to stem cell transformations induced 
by cell-permeable reprogramming factors. Scientific Reports 4: 4361. 
Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X., Hahm, H.S., Hao, 
E., Hayek, A., and Ding, S. (2009). A chemical platform for improved induction of human 
iPSCs. Nat Methods 6, 805-808. 
Lord, J.M., and Roberts, L.M. (1998). Toxin entry: retrograde transport through the secretory 
pathway. J Cell Biol 140, 733-736. 
Lyssiotis, C.A., Foreman, R.K., Staerk, J., Garcia, M., Mathur, D., Markoulaki, S., Hanna, J., 
Lairson, L.L., Charette, B.D., Bouchez, L.C., Bollong, M., Kunick, C., Brinker, A., Cho, C.Y., 
Schultz, P.G. and Jaenisch, R. (2009). Reprogramming if murine fibroblasts to induced 
pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U.S.A 106, 
8912-7. 
Mali, P., Chou, B.K., Yen, J., Ye, Z., Zou, J., Dowey, S., Brodsky, R.A., Ohm, J.E., Yu, W., 
Baylin, S.B., Yusa, K., Bradley, A., Meyers, D.J., Mukherjee, C., Cole, P.A and Cheng, L. 
(2010). Butyrate greatly enhances derivation of human induced pluripotent stem cells by 
promoting epigenetic remodelling and the expression of pluripotency-associated genes. Stem 
Cells 28, 713-20. 
Mann, D.A., and Frankel, A.D. (1991). Endocytosis and targeting of exogenous HIV-1 Tat 
protein. EMBO J 10, 1733-1739. 
Mi, Z., Mai, J., Lu, X., and Robbins, P.D. (2000). Characterization of a class of cationic peptides 
able to facilitate efficient protein transduction in vitro and in vivo. Mol Ther 2, 339-347. 
Mikkelsen, T.S, Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, B.E., 
Jaenisch, R., Lander, S., and Mesissner, A. (2008). Dissecting direct reprogramming through 
integrative genomic analysis. Nature 454, 49-55. 
Miyoshi, N., Ishii, H., Nagano, H., Haraguchi, N., Dewi, D.L., Kano, Y., Nishikawa, S., 
Tanemura, M., Mimori, K., Tanaka, F., Saito, T., Nishimura, J., Takemasa, I., Mizushima, T., 
Ikeda, M., Yamamoto, H., Sekimoto, M., Doki., Y and Mori, M. (2011). Reprogramming of 
mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8, 633-8. 
Nagahara, H., Vocero-Akbani, A.M., Snyder, E.L., Ho, A., Latham, D.G., Lissy, N.A., Becker-
Hapak, M., Ezhevsky, S.A., and Dowdy S.F. (1998). Transduction of full-length TAT fusion 
proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4, 1449-52. 
18 
 
Nemes, C., Varga, E., Polgar, Z., Klincumhom, N., Pirity, M.K., and Dinyes, A. (2014). 
Generation of mouse induced pluripotent stem cells by protein transduction. Tissue Eng Part 
C Methods 20, 383-92. 
Noguchi, H., and Matsumoto, S. (2006a). Protein transduction technology offers a novel 
therapeutic approach for diabetes. J Hepatobiliary Pancreat Surg 13, 306-313. 
Noguchi, H., and Matsumoto, S. (2006b). Protein transduction technology: a novel therapeutic 
perspective. Acta Med Okayama 60, 1-11. 
Noguchi, H., Matsushita, M., Okitsu, T., Moriwaki, A., Tomizawa, K., Kang, S., Li, S.T., 
Kobayashi, N., Matsumoto, S., Tanaka, K., Tanaka, N., and Matsui, H. (2004). A new cell-
permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 10, 305-
309. 
Nordin, F., Tye, G.J, Gaken, J., and Farzaneh, F. (2014). TATκ fusion protein of OCT-3/4 and 
KLF-4: Stable mixed population cell lines capable of delivering fusion proteins to target cells. 
J Cell Sci Ther 5(2):158. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313-7. 
Pan, C., Lu, B., Chen, H., and Bishop, C. (2010). Reprogramming human fibroblasts using 
HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Molecular Biology Reports 
37, 2117-2124. 
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., 
and Daley, G.Q. (2008). Reprogramming of human somatic cells to pluripotency with defined 
factors. Nature 451, 141-146. 
Prakash, O., Tang, Z.Y., He, Y.E., Ali, M.S., Coleman, R., Gill, J., Farr, G., and Samaniego, F. 
(2000). Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency 
type 1 tat-expressing transgenic mice. J Natl Cancer Inst 92, 721-728. 
Prochiantz, A. (2000). Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell 
Biol 12, 400-406. 
Rhee, Y.H., Ko, J.Y., Chang, M.Y., Yi, S.H., Kim, D., Kim, C.H., Shim, J.W., Jo, A.Y., Kim, 
B.W., Lee, H., Lee, S.H., Suh, W., Park, C.H., Koh, H.C., Lee, Y.S., Lanza, R., Kim, K.S., and 
Lee, S.H. (2011). Protein-based human iPS cells efficiently generate functional dopamine 
neurons and can treat a rat model of Parkinson disease. J Clin Invest 121, 2326-35. 
19 
 
Schlaeger, T.M., Daheron, L., Brickler, T.R., Entwisle, S., Chan, K., Cianci, A., DeVine, A., 
Ettenger, A., Fitzgerald, K., Godfrey, M., Gupta, D., McPherson, J., Malwadkar, P., Gupta, M., 
Bell, B., Doi, A., Jung, N., Li, X., Lynes, M.S., Brookes, E., Cherry, A.B., Demirbas, D., 
Tsankov, A.M., Zon, L.I., Rubin, L.L., Feinberg, AP., Meissner, A., Cowan, C.A., and Daley, 
G.Q. (2015). A comparison of non-integrating reprogramming methods. Nat Biotechnol 33, 58-
63. 
Schwarze, S.R., Hruska, K.A., and Dowdy, S.F. (2000). Protein transduction: unrestricted 
delivery into all cells? Trends Cell Biol 10, 290-295. 
Shi, Y., Desponts, C., Do, J.T., Hahm, H.S., Scholer, H.R and Ding, S. (2008). Induction of 
pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule 
compound. Cell Stem Cell 3, 568-74. 
Singh, A., Upadhyav, V., Upadhyav, A.K., Singh, S.M., and Panda, A.K. (2015). Protein 
recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb 
Cell Fact 25, 14:41 
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., 
Cooper, O., Mitalipova, M., Isacson, O., and Jaenisch, R. (2009). Parkinson’s disease patient-
derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-77. 
Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell. 126. 663-676. 
Takahashi, K., Okita, K., Nakagawa, M., and Yamanaka, S. (2007). Induction of pluripotent 
stem cells from fibroblast cultures. Nat Protoc 2, 3081-3089. 
Taranger, C.K., Noer, A., Sorenson, A.L., Hakelien, A.M., Boquest, A.C and Collas, P. (2005). 
Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic 
reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 16, 5719-35. 
Their, M., Munst, B., Mielke, S., and Edenhofer, F. (2012). Cellular reprogramming employing 
recombinant sox2 protein. Stem Cells Int 549846. 
Theunissen, T.W., Costa, Y., Radzisheuskaya, A., van Oosten, A.L., Lavial, F., Pain, B., 
Castro, L.F., and Silva, J.C. (2011). Reprogramming capacity of Nanog is functionally 
conserved in vertebrates and resides in a unique homeodomain. Development 138, 4853-65. 
Thier, M., Munst, B., and Edenhofer, F. (2010). Exploring refined conditions for reprogramming 
cells by recombinant Oct4 protein. Int J Dev Biol 54, 1713-1721. 
20 
 
Vives, E. (2003). Cellular uptake [correction of utake] of the Tat peptide: an endocytosis 
mechanism following ionic interactions. J Mol Recognit 16, 265-271. 
Vives, E., Brodin, P., and Lebleu, B. (1997). A truncated HIV-1 Tat protein basic domain rapidly 
translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 
272, 16010-16017. 
Wadia, J.S., and Dowdy, S.F. (2003). Modulation of cellular function by TAT mediated 
transduction of full length proteins. Curr Protein Pept Sci 4, 97-104. 
Wang, Y., and Adjaye, J. (2011). A cyclic AMP analog, 8-Br-cAMP, enhances the induction of 
pluripotency in human fibroblast cells. Stem Cell Rev 7, 331-341. 
Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, P.K., Smith, 
Z.D., Meissner, A., Daley, G.Q., Brack, A.S., Collins, J.J., Cowan, C., Schlaeger, T.M., and 
Rossi, D.J. (2010). Highly efficient reprogramming to pluripotency and directed differentiation 
of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630. 
Wender, P.A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L., and Rothbard, J.B. 
(2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular 
uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97, 13003-13008. 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, 
B.E., and Jaenisch, R. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-
like state. Nature 448, 318-324. 
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Milekovsky, M., Hamalainen, R., Cowling, 
R., Wang, W., Liu, P., Gertsenstein, M., Kaji, K., Sung, H.K., and Nagy, A. (2009). piggyBac 
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770. 
Wurm, F.M. (2004). Production of recombinant protein therapeutics in cultivated mammalian 
cells. Nat Biotechnol 22, 1393-1398. 
Xu, H., Tsang, K.S., Chan, J.C., Yuan, P., Fan, R., Kaneto, H., and Xu, G. (2013). The 
combined expression of Pdx1 and MafA with either Ngn3 or NeuroD improves the 
differentiation efficiency of mouse embryonic stem cells into insulin-producing cells. Cell 
Transplant 22, 147-58. 
Xu, J., Du, Y., and Deng, H. (2015). Direct lineage reprogramming: strategies, mechanisms, 
and applications. Cell Stem Cell 16, 119-34. 
Yamanaka, S. (2007). A fresh look at iPS cell. Cell 137, 13-7.  
21 
 
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, S., Slukvin, I.I., and Thomson, J.A. (2009). 
Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 
797-801. 
Zhang, Y., Ma, Y., Gu, J., Liao, B., Li, J., Wong, J., and Jin, Y. (2012). Reprogramming of 
somatic cells via TAT-mediated protein transduction of recombinant factors. Biomaterials 33, 
5047-5055. 
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., 
Siuzdak, G., Schöler, H.R., Duan, L., and Ding, S. (2009). Generation of Induced Pluripotent 
Stem Cells Using Recombinant Proteins. Cell Stem Cell 4, 381-384. 
Figure Caption 
  
22 
 
List of Figures 
Figure 1: The macropinocytosis model of protein transduction. The primary mechanism 
of protein transduction is an electrostatic interaction between PTD-conjugated 
macromolecules and the plasma membrane, followed by the penetration into cells by 
macropinocytosis, and release to the cytoplasm and nuclei by retrograde transport (Noguchi 
and Matsumoto, 2006a). 
Figure 2: Predicted α-helical wheels of original TAT and the synthesization of synthetic 
TAT peptides. The numbering indicates a sequential amino acid position; values in 
parentheses indicate the fold change of FITC emission normalized to original TAT peptide (A) 
(Adapted from Ho et al., 2001). 
Figure 3: A comparison of TAT-HIV, TAT33 and TATκ peptides. The blue-coloured letters 
indicate the replacement of the original amino acid in the original TAT-HIV domain. The green 
box within the TAT peptide indicates the presence of two Furin sites. 
A=Alanine; G=Glysine; K=Lysine; Q=Glutamine; R=Arginine; Y=Tyrosine. 
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Table 1: Amino acid sequence of characterized PTDs. 
PTD Amino acid sequence Length 
HIV-1 TAT Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arga 11 a.a 
HSV VP22 Asp-Ala-Ala-Thr-Ala-Thr-Arg-Gly-Arg-Ser-Ala-Ala-Ser-Arg-
Pro-Thr-Glu-Arg-Pro-Arg-Ala-Pro-Ala-Arg-Ser-Ala-Ser-Arg-
Pro-Arg-Arg-Pro-Val-Glu 
34 a.a 
Antp Arg-Gln-Iso-Lys-Iso-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-
Lys-Lys 
16 a.a 
Gly-Arg-Lys-Lys-Arg-Arg is a potential nuclear localization sequence. 
 
Ala-Alanine, Tyr-Tyrosine, Gly-Glycine, Arg-Arginine, Lys-Lysine, Gln-Glutamine, Asp-
Aspartic acid, Thr-Threonine, Ser-Serine, Pro-Proline, Phe-Phenylalanine, Trp-Trytophan, 
Met-Methionine. 
 
 
 
 
 
 
 
 
Table 2: A wide variety of macromolecules have been covalently fused to PTDs. 
Macromolecules PTD-conjugated Target cells references 
Protein/peptide TAT-β-galactosidase 
 
 
 
 
 
Rat salivary gland 
cell lines, organ 
culture, rat 
submandibular 
gland (in vivo) 
 
Murine HSCs 
 
(Barka et al., 2000) 
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TAT-HoxB4 
 
TAT-Zfx 
Murine HSCs  
(Krosl et al., 2003) 
 
(Xu et al., 2009) 
 
Antisense 
oligonucleotide 
 
 
A short peptide 
vector/oligonucleotide 
complexes (MPG)  
 
Human fibroblast 
HS68 and NIH3T3 
cell lines  
 
(Morris et al., 1997) 
 
 
 
Peptide nucleic  
acid (PNA) 
 
Phosphotyrosine 
phosphatases 
(PTPases) 
 
Pancreatic islets 
from rat 
 
(Ostenson et al., 2002) 
 
Iron beads/ 
nanoparticles 
 
 
Liposomes 
 
 
 
TAT-CLIO Super 
paramagnetic iron oxide 
(CLIO) 
 
large drug carriers, 200nm 
liposome-TAT 
 
Murine T-cells 
 
 
 
BT20 (human breast 
tumour), Lewis lung 
carcinoma (LLC, 
mouse lung 
carcinoma) and 
H9C2 (rat 
embryonic cardiac 
myocytes) 
 
 
(Dodd et al., 2001) 
 
 
(Torchilin et al., 2001) 
    
 
 
 
 
 
